Filed a patent for "targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes" on Tue, November 1, 2022
Filed a patent for "targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes" on Wed, December 14, 2022
